Infectious Complications and Multidrug-Resistant Bacteria in Patients With Hematopoietic Stem Cell Transplantation in the First 12 Months After Transplant

César-Arce, A.; Volkow-Fernández, Patricia; Valero-Saldaña, Luis Manuel; Acosta-Maldonado, Brenda Lizeth; Vilar‐Compte, Diana; Cornejo‐Juárez, Patricia

doi:10.1016/j.transproceed.2017.03.081

Cited by 11 publications

(15 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The risk of developing an ESBL-EB infection after a HSCT ranges from 0.4 to 3.5%, although most of the literature has been limited to bloodstream infections [25,31,32]. The majority of ESBL-EB infections are due to E. coli or K. pneumoniae [26,[31][32][33] that produce a CTX-M β-lactamase, although production of SHV and TEM β-lactamases has also been identified in this patient population [27,29,31,32]. In one retrospective cohort, the median time from HSCT to ESBL-EB infection was 141 days [32].…”

Section: Disease Epidemiology Esbl-producing Enterobacteralesmentioning

confidence: 99%

“…Among HSCT patients, the mortality associated with ESBL-EB infections is similarly high, with one study estimating a 1-year mortality of 52% for patients with multidrug-resistant infections, of which 87% of the multidrug-resistant isolates were ESBL-EB [33]. In neutropenic cancer patients, including those with HSCTs, the 30-day mortality rate associated with ESBL-EB bacteremia was reported to be 38% [27].…”

Section: Esbl-producing Enterobacteralesmentioning

confidence: 99%

“…In neutropenic cancer patients, including those with HSCTs, the 30-day mortality rate associated with ESBL-EB bacteremia was reported to be 38% [27]. Cancer patients with ESBL-EB bacteremia are suspected to have an increased mortality compared to patients without resistant organisms [27,29], although conflicting reports exist [30,33].…”

Section: Esbl-producing Enterobacteralesmentioning

confidence: 99%

See 2 more Smart Citations

Multidrug-Resistant Organisms: Posttransplant Management for Extended-Spectrum Beta-Lactamase Producers and Carbapenem-Resistant Enterobacterales

Howard‐Anderson¹,

Pouch²

2020

Emerging Transplant Infections

View full text Add to dashboard Cite

The incidence of extended-spectrum β-lactamase (ESBL)-producing Enterobacterales (ESBL-EB) and carbapenem-resistant Enterobacterales (CRE) infections has been increasing worldwide, although the prevalence and mechanism of resistance vary by geographic region and institutional patterns of resistance. These multidrug-resistant infections are challenging to diagnose and treat and can cause significant morbidity and mortality in transplant patients. In this chapter we highlight recent trends in epidemiology, including risk factors for acquiring ESBL-EB and CRE, clinical outcomes, and new strategies for

show abstract

Section: Disease Epidemiology Esbl-producing Enterobacteralesmentioning

confidence: 99%

Section: Esbl-producing Enterobacteralesmentioning

confidence: 99%

Section: Esbl-producing Enterobacteralesmentioning

confidence: 99%

See 1 more Smart Citation

Multidrug-Resistant Organisms: Posttransplant Management for Extended-Spectrum Beta-Lactamase Producers and Carbapenem-Resistant Enterobacterales

Howard‐Anderson¹,

Pouch²

2020

Emerging Transplant Infections

View full text Add to dashboard Cite

show abstract

“…It is recognized that the depressed immune system and frequent lesions in the gastrointestinal mucosa and skin barriers due to surgical interventions, invasive devices or cytotoxic chemotherapy, facilitate the translocation or invasion of tissues and bloodstream by ESBL-PE [11][12][13][14]. In addition, frequent use of antibiotics as prophylaxis or treatment has also been linked to increased ESBL-PE infections in cancer patients [15][16][17].…”

Section: Introductionmentioning

confidence: 99%

Development and validation of a scoring system for predicting cancer patients at risk of extended-spectrum b-lactamase-producing Enterobacteriaceae infections

et al. 2020

View full text Add to dashboard Cite

Background: Extended-spectrum beta-lactamase producing Enterobacteriaceae (ESBL-PE) infections are frequent and highly impact cancer patients. We developed and validated a scoring system to identify cancer patients harboring ESBL-PE at the National Institute of Cancer of Colombia. Methods: We retrospectively analyzed medical records of 1695 cancer patients. Derivation phase included 710 patients admitted between 2013 to 2015, ESBL-PE positive culture (n = 265) paired by month and hospitalization ward with Non-ESBL-PE (n = 445). A crude and weighted score was developed by conditional logistic regression. The model was evaluated in a Validation cohort (n = 985) with the same eligibility criteria between 2016 to 2017. Results: The score was based on eight variables (reported with Odds Ratio and 95% confidence interval): Hospitalization ≥7 days (5.39 [2.46-11.80]), Hospitalization during the previous year (4, 87 [2.99-7.93]), immunosuppressive therapy during the previous 3 months (2.97 [1.44-6.08]), Neutropenia (1.90 [1.12-3.24]), Exposure to Betalactams during previous month (1.61 [1.06-2.42]), Invasive devices (1.51 [1.012-2.25]), Neoplasia in remission (2.78 [1.25-1.17]), No chemotherapy during the previous 3 months (1.90 [1.22-2.97]). The model demonstrated an acceptable discriminatory capacity in the Derivation phase, but poor in the Validation phase (Recipient Operating Characteristic Curve: 0.68 and 0.55 respectively). Conclusions: Cancer patients have a high prevalence of risk factors for ESBL-PE infection. The scoring system did not adequately discriminate patients with ESBL-PE. In a high-risk population, other strategies should be sought to identify patients at risk of resistant ESBL-PE infection.

show abstract

“…It is recognized that the depressed immune system and frequent lesions in the gastrointestinal mucosa and skin barriers due to surgical interventions, invasive devices or cytotoxic chemotherapy, facilitate the translocation or invasion of the tissues or bloodstream by ESBL-PE (11)(12)(13)(14). In addition, frequent use of antibiotics as prophylaxis or treatment has also been linked to increased ESBL-PE infections in cancer patients (15)(16)(17).…”

Section: Introductionmentioning

confidence: 99%

Development and validation of a scoring system for predicting cancer patients at risk of extended-spectrum b-lactamase-producing Enterobacteriaceae infections.

Martinez-Valencia

Martínez

Ayala

et al. 2020

Preprint

View full text Add to dashboard Cite

KEYWORDS 2 beta-lactamases, extended-spectrum β-lactamase producing Enterobacteriaceae, cancer, prediction, risk stratification 3 Abstract Background: Extended-spectrum beta-lactamase producing Enterobacteriaceae (ESBL-PE) infections are frequent and highly impact cancer patients. We developed and validated a scoring system to identify cancer patients harboring ESBL-PE at the National Institute of Cancer of Colombia. Methods: We retrospectively analyzed medical records of 1695 cancer patients. Derivation phase included 710 patients admitted between 2013 to 2015, ESBL-PE positive culture (n = 265) paired by month and hospitalization room with Non-ESBL-PE (n = 445). A crude and weighted score was developed by conditional logistic regression. The model was evaluated in a Validation cohort (n = 985) with the same eligibility criteria between 2016 to 2017.Results: The score was based on eight variables (reported with Odds Ratio and 95% confidence interval): Hospitalization ≥7 days (5.39 [2.46 -11.80]), Hospitalization during the previous year (4 , 87 [2.99 -7.93]), immunosuppressive therapy during the previous 3 months (2.97 [1.44-6.08]), Neutropenia (1.90 [1.12 -3.24]), Exposure to Betalactams during previous month (1.61 [1.06 -2.42]), Invasive devices (1.51 [1.012 -2.25]), Neoplasia in remission (2.78 [1.25 -1.17]), No chemotherapy during the previous 3 months (1.90 [1.22 -2.97]). The model demonstrated an acceptable discriminatory capacity in the Derivation phase, but poor in the Validation phase (Recipient Operating Characteristic Curve: 0.68 and 0.55 respectively). Conclusions: Cancer patients have a high prevalence of risk factors for ESBL-PE infection. The scoring system did not adequately discriminate patients with ESBL-PE. In a high-risk population, other strategies should be sought to identify patients at risk of resistant ESBL-PE infection.

show abstract

Infectious Complications and Multidrug-Resistant Bacteria in Patients With Hematopoietic Stem Cell Transplantation in the First 12 Months After Transplant

Cited by 11 publications

References 19 publications

Multidrug-Resistant Organisms: Posttransplant Management for Extended-Spectrum Beta-Lactamase Producers and Carbapenem-Resistant Enterobacterales

Multidrug-Resistant Organisms: Posttransplant Management for Extended-Spectrum Beta-Lactamase Producers and Carbapenem-Resistant Enterobacterales

Development and validation of a scoring system for predicting cancer patients at risk of extended-spectrum b-lactamase-producing Enterobacteriaceae infections

Development and validation of a scoring system for predicting cancer patients at risk of extended-spectrum b-lactamase-producing Enterobacteriaceae infections.

Contact Info

Product

Resources

About